EXELIXIS, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Exelixis reported Q3 2026 total revenues of $658.7M (vs. $597.8M in Q3 2025), with net product revenues of $604.9M driven by cabozantinib franchise growth. GAAP diluted EPS was $0.85 ($0.94 non-GAAP); company maintained full-year 2026 guidance of $2.5–$2.55B total revenues. Key developments: zanzalintinib NDA for metastatic colorectal cancer has FDA PDUFA target date of March 3, 2027 (extended three months); phase 3 STELLAR-304 in renal cell carcinoma expected Q1 2027; Exelixis has repurchased $402.1M of stock YTD under its $750M authorized program (total $3.2B since March 2023); patent appeal upheld against MSN Laboratories, extending generic cabozantinib entry to January 15, 2030; settlement reached with Azurity for generic entry December 1, 2030.
Why this rating
Solid operational execution with revenue growth and pipeline progress, but no transformational news. Zanzalintinib approval remains uncertain; generic competitive threats extend but not resolved. Meaningful relative to company size but within normal business development cycle.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.